FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change

被引：23
作者：
Nathan, Steven D. [1 ]
Yang, Ming [2 ]
Morgenthien, Elizabeth A. [2 ]
Stauffer, John L. [2 ]
机构：
[1] Inova Fairfax Hosp, Falls Church, VA USA
[2] Genentech Inc, San Francisco, CA 94080 USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 55卷 / 05期
关键词：
FORCED VITAL CAPACITY; PIRFENIDONE; MORTALITY; TRIAL;
D O I：
10.1183/13993003.02151-2019
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：4
相关论文
共 15 条
[1]  
American Thoracic Society, 2005, PULM FUNCT LAB MAN P
[2]  
[Anonymous], 1987, Am Rev Respir Dis, V136, P1285
[3]   6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis [J].
du Bois, Roland M. ;
Albera, Carlo ;
Bradford, Williamson Z. ;
Costabel, Ulrich ;
Leff, Jonathan A. ;
Noble, Paul W. ;
Sahn, Steven A. ;
Valeyre, Dominique ;
Weycker, Derek ;
King, Talmadge E., Jr. .
EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (05) :1421-1429
[4]   Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials [J].
Durheim, Michael T. ;
Collard, Harold R. ;
Roberts, Rhonda S. ;
Brown, Kevin K. ;
Flaherty, Kevin R. ;
King, Talmadge E., Jr. ;
Palmer, Scott M. ;
Raghu, Ganesh ;
Snyder, Laurie D. ;
Anstrom, Kevin J. ;
Martinez, Fernando J. .
LANCET RESPIRATORY MEDICINE, 2015, 3 (05) :388-396
[5]   Standardization of Spirometry 2019 Update An Official American Thoracic Society and European Respiratory Society Technical Statement [J].
Graham, Brian L. ;
Steenbruggen, Irene ;
Barjaktarevic, Igor Z. ;
Cooper, Brendan G. ;
Hall, Graham L. ;
Hallstrand, Teal S. ;
Kaminsky, David A. ;
McCarthy, Kevin ;
McCormack, Meredith C. ;
Miller, Martin R. ;
Oropez, Cristine E. ;
Rosenfeld, Margaret ;
Stanojevic, Sanja ;
Swanney, Maureen P. ;
Thompson, Bruce R. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (08) :E70-E88
[6]   Spirometric reference values from a sample of the general US population [J].
Hankinson, JL ;
Odencrantz, JR ;
Fedan, KB .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (01) :179-187
[7]   A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis [J].
King, Talmadge E., Jr. ;
Bradford, Williamson Z. ;
Castro-Bernardini, Socorro ;
Fagan, Elizabeth A. ;
Glaspole, Ian ;
Glassberg, Marilyn K. ;
Gorina, Eduard ;
Hopkins, Peter M. ;
Kardatzke, David ;
Lancaster, Lisa ;
Lederer, David J. ;
Nathan, Steven D. ;
Pereira, Carlos A. ;
Sahn, Steven A. ;
Sussman, Robert ;
Swigris, Jeffrey J. ;
Noble, Paul W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2083-2092
[8]   Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis [J].
Nathan, Steven D. ;
Albera, Carlo ;
Bradford, Williamson Z. ;
Costabel, Ulrich ;
du Bois, Roland M. ;
Fagan, Elizabeth A. ;
Fishman, Robert S. ;
Glaspole, Ian ;
Glassberg, Marilyn K. ;
Glasscock, Kenneth F. ;
King, Talmadge E., Jr. ;
Lancaster, Lisa ;
Lederer, David J. ;
Lin, Zhengning ;
Pereira, Carlos A. ;
Swigris, Jeffrey J. ;
Valeyre, Dominique ;
Noble, Paul W. ;
Wells, Athol U. .
THORAX, 2016, 71 (05) :429-435
[9]   Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials [J].
Noble, Paul W. ;
Albera, Carlo ;
Bradford, Williamson Z. ;
Costabel, Ulrich ;
Glassberg, Marilyn K. ;
Kardatzke, David ;
King, Talmadge E., Jr. ;
Lancaster, Lisa ;
Sahn, Steven A. ;
Szwarcberg, Javier ;
Valeyre, Dominique ;
du Bois, Roland M. .
LANCET, 2011, 377 (9779) :1760-1769
[10]   Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis [J].
Paterniti, Miya O. ;
Bi, Youwei ;
Rekic, Dinko ;
Wang, Yaning ;
Karimi-Shah, Banu A. ;
Chowdhury, Badrul A. .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (09) :1395-1402
12